PBAC's latest decision on Triglycerides, medium chain: Recommended (2022). Considered for Ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency; and dietary management of conditions requiring a source of medium chain triglycerides (chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, fat malabsorption).
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Patients requiring a ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency; patients with chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, or fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders.
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Betaquik
Economic model
Cost-minimisation
ICER note
Not modelled; this is a cost-neutral brand replacement with identical nutritional content to the existing PBS-listed Betaquik.